Search - tctmd.com

Displaying 781 - 800 of 1295

Sort: Relevancy | Date

News Industry News

LivaNova Announces New Data Reaffirming Value of Perceval for Aortic Valve Replacement in Aortic Stenosis Patients

May 05, 2017

High-Volume Surgeons More Likely to Perform Durable Mitral Valve Repairs, Have Better Outcomes

News Daily News

High-Volume Surgeons More Likely to Perform Durable Mitral Valve Repairs, Have Better Outcomes

Michael O'Riordan

May 04, 2017

More Conservative Antibiotic Prophylaxis for Infective Endocarditis Seems Safe, Appropriate

News Daily News

More Conservative Antibiotic Prophylaxis for Infective Endocarditis Seems Safe, Appropriate

April 28, 2017

TCTMD’s Top 10 Most Popular Stories for April 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

April 28, 2017

News Industry News

NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation

April 26, 2017

News Daily News

Novel Percutaneous Technique May Allow for TMVR in Patients at High Risk for LVOT Obstruction

Yael L. Maxwell

April 18, 2017

Comrades in TAVR? Cardiac Surgeons Say They’re Involved in All Stages of TAVR Care

News Daily News

Comrades in TAVR? Cardiac Surgeons Say They’re Involved in All Stages of TAVR Care

Yael L. Maxwell

April 14, 2017

Navigating and Negotiating Your First Job Contract

News Opinion Fellow Talk

Navigating and Negotiating Your First Job Contract

Rahul Sharma, MD

April 11, 2017

SCOUTing the ‘Forgotten Valve’: Promise for a New Percutaneous Treatment Option in Tricuspid Regurgitation

News Daily News

SCOUTing the ‘Forgotten Valve’: Promise for a New Percutaneous Treatment Option in Tricuspid Regurgitation

Yael L. Maxwell

April 04, 2017

Living or Leaving: Does Palliative Care Deserve a Place at the TAVR Table?

News Features

Living or Leaving: Does Palliative Care Deserve a Place at the TAVR Table?

March 31, 2017

News Daily News

Boston Scientific Adds Two More TAVR Valves With Symetis Purchase

Michael O'Riordan

March 30, 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

March 27, 2017

MitraClip for Tricuspid Regurgitation Gains Traction but Still in Preliminary Stages

News Daily News

MitraClip for Tricuspid Regurgitation Gains Traction but Still in Preliminary Stages

Yael L. Maxwell

March 27, 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

March 24, 2017

Post-TAVR, Nearly a Quarter of Patients Show New Signs of Silent Cerebral Microbleeds on MRI

News Conference News ACC 2017

Post-TAVR, Nearly a Quarter of Patients Show New Signs of Silent Cerebral Microbleeds on MRI

March 20, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

March 15, 2017

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.